Adjuvant therapy 'cuts risk of brain metastases' in NSCLC
Osimertinib is a practice-changing treatment for certain patients with completely resected EGFR-mutated disease, author says
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
In people with resectable non-small cell lung cancer (NSCLC) who have a mutated epidermal growth factor receptor gene (EGFR), adjuvant osimertinib reduces the risk of a brain metastasis within 18 months to below 1%, trial results show.
Delegates at the European Society for Medical Oncology (ESMO) virtual congress 2020 were told about an exploratory analysis of results from the ADAURA